CJC-1295: The Complete 2026 Research Guide to Growth Hormone Secretagogues

CJC-1295 occupies a unique position in peptide research: it is one of the most extensively characterized growth hormone-releasing hormone (GHRH) analogs ever synthesized, with documented human pharmacokinetic data dating back nearly two decades and an active 2025–2026 research profile. Yet despite this depth, many researchers encounter significant confusion around the two distinct forms of the compound, their mechanisms, and their appropriate research contexts.

This guide covers everything a researcher needs to understand CJC-1295 — from its molecular design rationale to its established protocols, synergistic stacking with Ipamorelin, and the latest 2026 findings from the literature.

What Is CJC-1295?

CJC-1295 is a synthetic 30-amino acid peptide analog of endogenous growth hormone-releasing hormone (GHRH 1-29). Endogenous GHRH is produced in the hypothalamus and travels via the hypophyseal portal circulation to the anterior pituitary, where it binds GHRH receptors on somatotroph cells and stimulates growth hormone synthesis and secretion.

The limitation of native GHRH for research purposes is its extremely short plasma half-life — approximately 7 minutes in circulation — due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and other serum proteases. CJC-1295 was engineered to overcome this limitation through strategic amino acid substitutions that confer DPP-IV resistance while preserving GHRH receptor binding affinity.

Historical Development

CJC-1295 was developed by ConjuChem Biotechnologies in Canada in the early 2000s. The “CJC” designation refers to ConjuChem, and the compound was initially designated CJC-1295 in the company’s internal pipeline. The foundational human pharmacokinetic data was published in 2006 in the Journal of Clinical Endocrinology and Metabolism by Alba M et al. (PMID: 16352683), establishing the compound’s prolonged GH-stimulating profile in human subjects.

CJC-1295 DAC vs. CJC-1295 (No DAC): A Critical Distinction

The single most important concept for researchers working with CJC-1295 is understanding the two distinct variants in circulation:

CJC-1295 Without DAC (Modified GRF 1-29)

Sometimes called “Mod GRF 1-29,” CJC-1295 without the Drug Affinity Complex retains the DPP-IV resistance modifications (substitutions at positions 2, 8, 15, and 27) but lacks the bioconjugation chemistry that enables albumin binding. Its plasma half-life is approximately 25–30 minutes — dramatically longer than native GHRH’s 7 minutes, but still suitable for producing discrete GH pulses that closely mimic the physiological pulsatile secretion pattern.

In research protocols, CJC-1295 without DAC is typically administered more frequently (daily or multiple times per day) precisely because researchers want to study GH secretion in the context of natural pulsatile dynamics rather than a sustained GH bleed.

CJC-1295 DAC (With Drug Affinity Complex)

The DAC-modified version incorporates a maleimidoproprionic acid (MPA) bioconjugation moiety at the C-terminus that reacts with free thiol groups on circulating albumin. This covalent albumin binding extends the compound’s effective half-life to 6–8 days — a 50–80× increase over native GHRH.

The consequence of this extended half-life is a fundamentally different GH secretion profile: rather than discrete pulses, CJC-1295 DAC produces a sustained elevation of basal GH levels (sometimes described as a “GH bleed” in the literature). Mean GH area-under-the-curve over 14 days is substantially greater with DAC than without.

Mechanism of Action: How CJC-1295 Stimulates GH Release

CJC-1295’s mechanism operates through the GHRH receptor (GHRHR), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. When CJC-1295 binds GHRHR, the following signaling cascade occurs:

1. Gαs activation — receptor coupling to stimulatory G protein activates adenylyl cyclase
2. cAMP elevation — increased intracellular cyclic AMP activates protein kinase A (PKA)
3. Transcription and synthesis — PKA phosphorylates CREB, upregulating GH gene transcription and increasing somatotroph synthesis capacity
4. Calcium influx — parallel PKA-independent pathway activates voltage-gated calcium channels, triggering GH exocytosis from secretory granules
5. Somatostatin inhibition — GHRH signaling also suppresses hypothalamic somatostatin release, removing the inhibitory brake on GH secretion

This last point is particularly important for understanding why CJC-1295 stacking with Ipamorelin produces synergistic effects — more on that below.

GH/IGF-1 Axis Effects

Elevated GH, in turn, stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of GH’s downstream effects on tissue growth, protein synthesis, lipolysis, and bone metabolism. In the original CJC-1295 human trial (PMID 16352683), IGF-1 levels remained elevated for up to 14 days after a single CJC-1295 DAC injection — substantially longer than the GH elevation itself — reflecting IGF-1’s longer half-life and the hepatic reservoir effect.

The Original Human Trial: What the Data Shows

The 2006 Phase 1/2 clinical trial by Alba et al. (PMID: 16352683) published in the Journal of Clinical Endocrinology and Metabolism remains the cornerstone reference for CJC-1295 pharmacology. Key findings:

• Dose range studied: 30, 60, 125, 250 mcg/kg subcutaneous single injection in healthy adults aged 21–61
• GH response: Mean GH levels increased 2–10× over baseline at 2–6 hours post-injection, persisting in elevated state for approximately 6 days
• IGF-1 response: Serum IGF-1 increased 1.5–3× over baseline with elevations sustained for 9–14 days in higher dose groups
• Dose-response relationship: Clear dose-dependent effects observed across the tested range, with 125 mcg/kg and 250 mcg/kg showing comparable GH and IGF-1 responses suggesting near-maximal receptor occupancy at 125 mcg/kg
• Safety profile: Generally well-tolerated with transient injection site reactions; no serious adverse events reported

CJC-1295 and Ipamorelin: Research on the Synergistic Stack

CJC-1295 is perhaps most frequently studied in combination with Ipamorelin, a selective GHSR-1a (ghrelin receptor) agonist. The mechanistic rationale for this combination is well-established:

Dual-Pathway Activation

• CJC-1295 pathway: GHRHR activation → cAMP → GH synthesis + somatostatin suppression
• Ipamorelin pathway: GHSR-1a activation → phospholipase C → IP3/DAG → calcium mobilization → GH exocytosis

These pathways converge at the somatotroph but through distinct intracellular messengers, meaning they don’t compete for the same rate-limiting signaling steps. The result in research models is supraadditive GH pulse amplitude — greater than what either compound produces individually.

Additionally, CJC-1295’s somatostatin-suppressing effect removes the inhibitory brake that would otherwise attenuate Ipamorelin’s GH-stimulating effect. Ipamorelin, in turn, amplifies the GH secretory response at the level of the somatotroph itself. This makes the combination a particularly well-characterized model for maximal GHRH-pathway stimulation in preclinical research.

🔗 See our dedicated guide: CJC-1295 + Ipamorelin Blend: Growth Hormone Research Guide

CJC-1295 vs. Tesamorelin: Comparative Research Context

Both CJC-1295 and Tesamorelin are GHRH analogs studied for their effects on the GH/IGF-1 axis, but they differ in structural modifications, half-life, and primary research contexts:

• Tesamorelin is trans-3-hexenoic acid-conjugated GHRH with a half-life of approximately 26 minutes (similar to CJC-1295 without DAC), requiring daily administration. It has been the subject of Phase 3 clinical trials specifically in HIV-associated lipodystrophy models.
• CJC-1295 DAC with its 6–8 day half-life is more appropriate for research protocols requiring less frequent dosing and sustained GH/IGF-1 elevation over extended study periods.
• For research examining pulsatile GH dynamics, CJC-1295 without DAC and Tesamorelin are both appropriate models; for research examining the sustained GH/IGF-1 elevation state, CJC-1295 DAC has no direct analog with equivalent duration.

🔗 For a detailed comparison: Tesamorelin vs. CJC-1295: Growth Hormone Peptides Compared

Research Protocols: Dosing Frameworks from the Literature

The following protocol frameworks are derived from published preclinical and clinical research. They are provided for research reference purposes only.

CJC-1295 Without DAC (Pulsatile Protocol)

Because of its ~30-minute half-life, CJC-1295 without DAC requires administration timing that aligns with natural GH pulse windows — typically during the early sleep period or fasting state in animal models, when endogenous GH pulses are highest and somatostatin tone is lowest.

• Typical research dose range: 100–300 mcg/injection in rodent models (weight-scaled)
• Frequency: 1–3 injections per day
• Protocol duration: 4–12 weeks in most published protocols

CJC-1295 DAC (Sustained Protocol)

• Typical research dose range: 30–250 mcg/kg (human data from PMID 16352683)
• Frequency: Once weekly (given 6–8 day half-life)
• GH monitoring window: Peak at 2–6 hours post-injection; sustained elevation for ~6 days
• IGF-1 monitoring: Elevation detectable for 9–14 days post-injection

2026 Research Update: Detection and Analytical Advances

Research utility of CJC-1295 continues to expand as analytical methods improve the ability to quantify GHRH analogs in biological matrices at physiologically relevant concentrations.

A January 2026 study published in the Journal of Pharmaceutical and Biomedical Analysis (PMID: 41138283) reported a nano-LC method coupled with quadrupole/Orbitrap mass spectrometry capable of detecting GHRH analogs including CJC-1295 variants in urine matrices. This analytical advance enables:

• Precise plasma-level tracking in in vivo pharmacokinetic studies
• Verification of albumin-binding kinetics for DAC-modified variants
• Metabolite identification to better characterize degradation pathways

As these detection methods proliferate, researchers gain significantly more precise tools for dose-response characterization and interindividual variability assessment in GHRH analog research.

Ongoing research in 2025–2026 continues to examine CJC-1295’s effects in aging animal models, particularly in the context of age-related GH/IGF-1 axis decline and its downstream effects on body composition, bone mineral density, and metabolic function.

Research Safety Profile

Based on the existing literature, including the Phase 1/2 human trial (PMID 16352683) and multiple preclinical studies, CJC-1295’s documented effects in research models include:

• Dose-dependent elevation of GH and IGF-1
• Transient injection site reactions (most common reported finding in human data)
• Flushing in some subjects (attributed to rapid GH pulse at peak)
• No reported serious adverse events in the published human trial at doses up to 250 mcg/kg

As with all research peptides, effects observed in preclinical models do not necessarily translate to human outcomes, and all findings should be interpreted within the context of the specific research model employed.

Where CJC-1295 Fits in the GH Secretagogue Research Landscape

The GH secretagogue research toolkit as of 2026 includes several compound classes that researchers often position in relation to one another:

• GHRH analogs (CJC-1295, Tesamorelin): Stimulate GH via GHRHR; preserve somatostatin feedback loop; produce physiologically-patterned GH pulses or sustained elevation depending on variant
• Ghrelin receptor agonists (Ipamorelin, GHRP-6, GHRP-2): Stimulate GH via GHSR-1a; work synergistically with GHRH analogs; Ipamorelin has high GH selectivity relative to cortisol/prolactin
• Small molecule GH secretagogues (MK-677/Ibutamoren): Oral bioavailability; GHSR-1a agonism; longer half-life than peptide GHRPs

CJC-1295 occupies a distinctive niche in this landscape as the only GHRH analog with human pharmacokinetic data demonstrating multi-week GH/IGF-1 elevation from a single administration — making it a uniquely characterized tool for sustained GH axis research.

---

Research Disclaimer: CJC-1295 is sold by Spartan Peptides for laboratory and in vitro research purposes only. It is not approved for human use, and all information in this article is provided for educational and scientific reference purposes. Not for human consumption.